Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 267

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

Open access
Ding, Zhenyu, Li, Qing, Zhang, Rui, Xie, Li, Shu, Yang, Gao, Song, Wang, Peipei, Su, Xiaoqing, Qin, Yun, Wang, Yuelan, Fang, Juemin, Zhu, Zhongzheng, Xia, Xuyang, Wei, Guochao, Wang, Hui, Qian, Hong, Guo, Xianling, Gao, Zhibo, Wang, Yu, Wei, Yuquan, Xu, Qing, Xu, Heng, Yang, Li · 2021 · Signal Transduction and Targeted Therapy

Abstract

Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high tumor specificity and immunogenicity. Dendritic cell (DCs) vaccines based on neoantigens have exciting effects in treatment of some malignant tumors and are a promising therapeutic modality. Lung cancer is a lethal disease with the highest morbidity and mortality rate in the world. Despite the rapid development of targeted therapy and immune checkpoint inhibitors for lung cancer in recent years, their efficacy is still unsatisfactory overall. Therefore, there is an urgent unmet clinical need for lung cancer treatment. Here, we attempted to treat lung cancer using a personalized neoantigen peptide-pulsed autologous DC vaccine and conducted a single-arm, 2 medical centers, pilot study initiated by the investigator (ChiCTR-ONC-16009100, NCT02956551). The patients enrolled were patients with heavily treated metastatic lung cancer. Candidate neoantigens were derived from whole-exome sequencing and RNA sequencing of fresh biopsy tissues as well as bioinformatics analysis. A total of 12 patients were enrolled in this study. A total of 85 vaccine treatments were administered with a median value of 5 doses/person (range: 3–14 doses/person). In total, 12–30 peptide-based neoantigens were selected for each patient. All treatment-related adverse events were grade 1–2 and there were no delays in dosing due to toxic effects. The objective effectiveness rate was 25%; the disease control rate was 75%; the median progression-free survival was 5.5 months and the median overall survival was 7.9 months. This study provides new evidence for neoantigen vaccine therapy and new therapeutic opportunities for lung cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-00448-5

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 267

Metadata

Authors
Ding, Z., Li, Q., Zhang, R., Xie, L., Shu, Y., Gao, S., Wang, P., Su, X., Qin, Y., Wang, Y., Fang, J., Zhu, Z., Xia, X., Wei, G., Wang, H., Qian, H., Guo, X., Gao, Z., Wang, Y., Wei, Y., Xu, Q., Xu, H., & Yang, L.
Venue
Signal Transduction and Targeted Therapy
Published
2021-01-20
Volume
6
Issue
1
Pages
26-26
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3123510155
Cited by
267
References
50
FWCI
13.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. https://app.cochat.ai/papers/10.1038/s41392-020-00448-5
The paper
Ding, Z., Li, Q., Zhang, R., Xie, L., Shu, Y., Gao, S., Wang, P., Su, X., Qin, Y., Wang, Y., Fang, J., Zhu, Z., Xia, X., Wei, G., Wang, H., Qian, H., Guo, X., Gao, Z., Wang, Y., . . . Yang, L. (2021). Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-00448-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.